Literature DB >> 17374953

Cognitive functioning and brain MRI in patients with type 1 and type 2 diabetes mellitus: a comparative study.

Augustina M A Brands1, Geert Jan Biessels, L Jaap Kappelle, Edward H F de Haan, Harold W de Valk, Ale Algra, Roy P C Kessels.   

Abstract

BACKGROUND/AIMS: Diabetes mellitus (DM) may affect the central nervous system, resulting in cognitive impairments. It has been suggested that cognitive impairments are more pronounced in DM2 than in DM1, but studies that directly compare the effects of these 2 types of DM on cognition are lacking.
METHODS: Forty patients with DM1 (mean duration: 34 years) were compared with 40 age- and education-matched patients who were known to have DM2 (mean duration: 7 years). Extensive neuropsychological assessment focussed on abstract reasoning, memory, attention and executive function, visuoconstruction and information processing speed. Psychological well-being was measured and brain MRIs were obtained.
RESULTS: No systematic between-group differences were observed in neuropsychological measures or levels of psychological well-being. DM2 patients showed significantly more deep white matter lesions and cortical atrophy on MRI (p < 0.01).
CONCLUSION: DM1 patients with more than 30 years of DM have a similar cognitive profile and better MRI ratings than age- and education-matched DM2 patients with only 7 years of DM. Copyright 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2007        PMID: 17374953     DOI: 10.1159/000100980

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  27 in total

1.  Early visual cortical structural changes in diabetic patients without diabetic retinopathy.

Authors:  Fábio S Ferreira; João M S Pereira; Aldina Reis; Mafalda Sanches; João V Duarte; Leonor Gomes; Carolina Moreno; Miguel Castelo-Branco
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-08-04       Impact factor: 3.117

Review 2.  Diabetes type II: a risk factor for depression-Parkinson-Alzheimer?

Authors:  Peter Riederer; Jasmin Bartl; Gerd Laux; Edna Grünblatt
Journal:  Neurotox Res       Date:  2010-06-15       Impact factor: 3.911

Review 3.  GluT4: A central player in hippocampal memory and brain insulin resistance.

Authors:  Ewan C McNay; Jiah Pearson-Leary
Journal:  Exp Neurol       Date:  2019-10-12       Impact factor: 5.330

4.  Activation of Hippocampal CREB by Rolipram Partially Recovers Balance Between TNF-α and IL-10 Levels and Improves Cognitive Deficits in Diabetic Rats.

Authors:  Ya Miao; Ting He; Yitong Zhu; Wei Li; Beiyuan Wang; Yuan Zhong
Journal:  Cell Mol Neurobiol       Date:  2015-05-23       Impact factor: 5.046

5.  Caffeine prevents weight gain and cognitive impairment caused by a high-fat diet while elevating hippocampal BDNF.

Authors:  Gregory A Moy; Ewan C McNay
Journal:  Physiol Behav       Date:  2012-12-06

Review 6.  The synergistic effects of HIV, diabetes, and aging on cognition: implications for practice and research.

Authors:  David E Vance; Pariya L Fazeli; Joan E Dodson; Michelle Ackerman; Michele Talley; Susan J Appel
Journal:  J Neurosci Nurs       Date:  2014-10       Impact factor: 1.230

7.  Insulin and IGF-I prevent brain atrophy and DNA loss in diabetes.

Authors:  Predrag Serbedzija; James E Madl; Douglas N Ishii
Journal:  Brain Res       Date:  2009-09-23       Impact factor: 3.252

8.  Hyperglycaemia and diabetes impair gap junctional communication among astrocytes.

Authors:  Gautam K Gandhi; Kelly K Ball; Nancy F Cruz; Gerald A Dienel
Journal:  ASN Neuro       Date:  2010-03-15       Impact factor: 4.146

9.  Receptor for advanced glycation end products: its role in Alzheimer's disease and other neurological diseases.

Authors:  Lih-Fen Lue; Douglas Gordon Walker; Sandra Jacobson; Marwan Sabbagh
Journal:  Future Neurol       Date:  2009

10.  Cranial volume, mild cognitive deficits, and functional limitations associated with diabetes in a community sample.

Authors:  Andrea L Christman; Tracy D Vannorsdall; Godfrey D Pearlson; Felicia Hill-Briggs; David J Schretlen
Journal:  Arch Clin Neuropsychol       Date:  2009-11-25       Impact factor: 2.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.